Detection of EGFR and BRAF mutations by competitive allele-specific TaqMan polymerase chain reaction in lung adenocarcinoma.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Oncology Letters

• Publication date

  2017-12-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.3892/ol.2017.7652PMID 29467863PMCID PMC5778904
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.

  2016influential reference
• EGFR-tyrosine kinase inhibitor treatment in a patient with advanced non-small cell lung cancer and concurrent exon 19 and 21 EGFR mutations: A case report and review of the literature.

  2016influential reference
• Validation of targeted next-generation sequencing for RAS mutation detection in FFPE colorectal cancer tissues: comparison with Sanger sequencing and ARMS-Scorpion real-time PCR

  2016cited by this paper
• Consolidation Chemotherapy After Concurrent Chemoradiotherapy in Patients With Stage III Non-Small-Cell Lung Cancer.

  2016cited by this paper
• Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.

  2016influential reference
• Abstract P2-09-20: Evaluation on the mutation screening by next-generation sequencing in hereditary breast and ovarian cancer: Implementation of recurrent mutation panel

  2016cited by this paper
• Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation–positive non-small cell lung cancers: an update for recent advances in therapeutics

  2016cited by this paper
• The next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy response

  2016cited by this paper
• therascreen® EGFR RGQ PCR Kit: A Companion Diagnostic for Afatinib and Gefitinib in Non-Small Cell Lung Cancer

  2016cited by this paper
• A targeted next-generation sequencing method for identifying clinically relevant mutation profiles in lung adenocarcinoma

  2016cited by this paper
• Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.

  2016cited by this paper
• Comparison of Next-Generation Sequencing, Quantitative PCR, and Sanger Sequencing for Mutation Profiling of EGFR, KRAS, PIK3CA and BRAF in Clinical Lung Tumors.

  2016cited by this paper
• Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches

  2016cited by this paper
• Non-p.V600E BRAF Mutations Are Common Using a More Sensitive and Broad Detection Tool.

  2015influential reference
• Global cancer statistics, 2012

  2015cited by this paper
• Disagreement in genotyping results of drug resistance alleles of the Plasmodium falciparum dihydrofolate reductase (Pfdhfr) gene by allele-specific PCR (ASPCR) assays and Sanger sequencing

  2015cited by this paper
• Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer

  2015influential reference
• New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?

  2015cited by this paper
• Clinical detection and categorization of uncommon and concomitant mutations involving BRAF

  2015cited by this paper
• Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology – Mainland China Subset Analysis of the PIONEER study

  2015influential reference
• KRAS Mutation Analysis by PCR: A Comparison of Two Methods

  2015cited by this paper
• Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma.

  2015cited by this paper
• Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis?

  2014cited by this paper
• Personalized treatment options in Non-small Cell Lung Cancer

  2014cited by this paper
• BRAF Mutations in Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

  2014cited by this paper
• Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations

  2014cited by this paper
• 1175OEGFR MUTATION AND SURVIVAL OUTCOMES IN PATIENTS WITH COMPLETELY RESECTED LUNG ADENOCARCINOMA - A MULTIPLE CENTERS, NON-INTERVENTIONAL STUDY (ICAN TRIAL).

  2014cited by this paper
• Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing.

  2014cited by this paper
• TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR

  2014cited by this paper
• BRAF mutations in non-small-cell lung cancer.

  2014cited by this paper
• BRAF-mutations in non-small cell lung cancer.

  2014cited by this paper
• First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

  2014cited by this paper
• The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial

  2014cited by this paper
• Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.

  2014influential reference
• Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer

  2013influential reference
• Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor

  2013cited by this paper
• Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.

  2013influential reference
• DISSECT Method Using PNA-LNA Clamp Improves Detection of EGFR T790m Mutation

  2013cited by this paper
• Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

  2013cited by this paper
• Concurrent driver mutations in non-small cell lung cancer (NSCLC) patients (p) on targeted therapy uncovered by comprehensive molecular profiling.

  2013cited by this paper
• Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer.

  2013cited by this paper
• Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer

  2013influential reference
• Detection of EGFR Mutations by TaqMan Mutation Detection Assays Powered by Competitive Allele-Specific TaqMan PCR Technology

  2013influential reference
• Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

  2013cited by this paper
• Clinical investigation of EGFR mutation detection by pyrosequencing in lung cancer patients.

  2013cited by this paper
• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

  2012cited by this paper
• Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples.

  2012influential reference
• Abstract 2100: Cancer biomarker research using castPCR technology

  2012cited by this paper
• Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status

  2012cited by this paper
• Braf and erbB2 mutations correlate with smoking status in lung cancer patients.

  2012influential reference
• Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

  2012cited by this paper
• Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy

  2012cited by this paper
• How novel molecular diagnostic technologies and biomarkers are revolutionizing genetic testing and patient care

  2012cited by this paper
• Highly Sensitive Detection of EGFR T790M Mutation Using Colony Hybridization Predicts Favorable Prognosis of Patients with Lung Cancer Harboring Activating EGFR Mutation

  2012cited by this paper
• Abstract 2087: Detection of KRAS mutations in circulating tumor cells (CTCs) and in formalin-fixed, paraffin-embedded (FFPE) tissue using castPCR method

  2012cited by this paper
• New driver mutations in non-small-cell lung cancer.

  2011influential reference
• Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer

  2011cited by this paper
• Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas

  2011cited by this paper
• Treatment of advanced non small cell lung cancer.

  2011cited by this paper
• Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer.

  2011cited by this paper
• A Noninvasive System for Monitoring Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Plasma DNA

  2011cited by this paper
• Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations

  2011cited by this paper
• Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay

  2011cited by this paper
• Detection of low‐level EGFR T790M mutation in lung cancer tissues

  2011cited by this paper
• Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

  2011cited by this paper
• Abstract 3071: Accurate and sensitive detection of KRAS mutations in heterogeneous cancer specimens

  2011cited by this paper
• Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.

  2011influential reference
• Abstract 2117: Detection of rare mutations in patient samples by comparative allele-specific TaqMan® assay-based PCR (CastPCR)

  2010cited by this paper
• Direct detection of Rare Circulating Tumor Cells in Blood by CastPCR.

  2010cited by this paper
• Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

  2010cited by this paper
• Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation

  2010cited by this paper
• Complex Mutations in the Epidermal Growth Factor Receptor Gene in Non-small Cell Lung Cancer

  2010cited by this paper
• Rapid detection of the epidermal growth factor receptor mutation in non-small-cell lung cancer for analysis of acquired resistance using molecular beacons.

  2010cited by this paper
• Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

  2010cited by this paper
• TNM Classification of Malignant Tumors, 7th edition

  2010influential reference
• Clinicopathologic and Molecular Features of Epidermal Growth Factor Receptor T790M Mutation and c-MET Amplification in Tyrosine Kinase Inhibitor-resistant Chinese Non-small Cell Lung Cancer

  2009cited by this paper
• Epidermal growth factor receptor (EGFR) double-activating somatic mutations in exons 19 and 21 in Japanese non-small cell lung cancer patients.

  2009influential reference
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

  2009influential reference
• EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases

  2009cited by this paper
• Coamplification at lower denaturation temperature-PCR increases mutation-detection selectivity of TaqMan-based real-time PCR.

  2009cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• Detection of mutations in EGFR in circulating lung-cancer cells.

  2008cited by this paper
• Genetic predictors of MEK dependence in non-small cell lung cancer.

  2008influential reference
• Peptide nucleic acid–locked nucleic acid polymerase chain reaction clamp‐based detection test for gefitinib‐refractory T790M epidermal growth factor receptor mutation

  2008cited by this paper
• First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

  2008cited by this paper
• Epidermal growth factor receptor double activating mutations involving both exons 19 and 21 exist in Chinese non-small cell lung cancer patients.

  2007influential reference
• Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.

  2006cited by this paper
• Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer

  2005influential reference
• A genome-based strategy uncovers frequent BRAF mutations in melanoma.

  2002cited by this paper
• Can we speed up the online publishing process? And who will pay for it, anyway?

  2002cited by this paper
• 95-kilodalton B-Raf serine/threonine kinase: identification of the protein and its major autophosphorylation site

  1992cited by this paper
• Free DNA in the serum of cancer patients and the effect of therapy.

  1977influential reference

• Chemotherapy of breast cancer cells alters susceptibility to complement-mediated opsonization and killing

  2025cites this paper
• Intermittent afatinib treatment suppresses the growth of resistant T790M-H1975 cells in non-small cell lung cancer (NSCLC) co-culture

  2025cites this paper
• Primer consenso interinstitucional de neoplasias mieloproliferativas crónicas

  2023influential citation
• BRAF V600E Mutation Test in Fine Needle Aspiration (FNA) Specimens of Thyroid Nodules by Competitive Allele-Specific TaqMan PCR (castPCR)

  2023influential citation
• Detection of IDH1 Mutation in cfDNA and Tissue of Adult Diffuse Glioma with Allele-Specific qPCR

  2023influential citation
• Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?

  2022cites this paper
• Significant position of C-myc in colorectal cancer: a promising therapeutic target

  2022cites this paper
• Driver and novel genes correlated with metastasis of non-small cell lung cancer: A comprehensive analysis.

  2021cites this paper
• Single-copy detection of somatic variants from solid and liquid biopsy

  2021cites this paper
• Taqman-MGB nanoPCR for Highly Specific Detection of Single-Base Mutations

  2021cites this paper
• Serum sHLA-G: Significant diagnostic biomarker with respect to therapy and immunosuppressive mediators in Head and Neck Squamous Cell Carcinoma

  2020cites this paper
• OTT_A_219703 8023..8031

  2019cites this paper
• Detection Of Mutations In The Isocitrate Dehydrogenase Genes (IDH1/IDH2) Using castPCRTM In Patients With AML And Their Clinical Impact In Mexico City

  2019cites this paper
• Multiple primary malignant neoplasms: A case report and literature review

  2019cites this paper
• Longitudinal assessment of peripheral blood BRAFV600E levels in patients with Langerhans cell histiocytosis

  2018cites this paper